{"success":true,"data":{"pressRelease":{"id":"167649","rtpr_id":"nACSngdGWa-20261013","ticker":"ANIX","exchange":"NASDAQ","all_tickers":["ANIX"],"title":"Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine","author":"ACCESSWIRE","published_at":"2026-10-13T13:00:01.070Z","article_body":"ORLANDO, FL / ACCESS Newswire (https://www.accessnewswire.com/) / October 13,\n2026 / RedChip Companies will host an investor webinar on Tuesday, October 20,\n2026, at 4:15 p.m. ET with Anixa Biosciences, Inc. (Nasdaq:ANIX), a\nclinical-stage biotechnology company developing first-in-class therapies to\ntreat and potentially prevent cancer.\n\nThe exclusive event will feature Dr. Amit Kumar, Chairman and CEO, who will\ndiscuss Anixa's two clinical-stage oncology programs: lira-cel, a novel CAR-T\ntherapy for recurrent, treatment-resistant ovarian cancer, and a breast cancer\nvaccine with therapeutic and preventive potential. Both programs are being\nadvanced through collaborations with leading research institutions, Moffitt\nCancer Center and Cleveland Clinic.\n\nDr. Kumar will review progress in the Phase 1 trial of lira-cel, an\nFSHR-targeted CAR-T therapy designed to attack both ovarian cancer cells and\ntumor-associated blood vessels. Early clinical observations include\nencouraging survival in heavily pretreated patients, with one patient\nsurviving nearly 2.5 years following treatment, and the first patient at the\ncurrent dose level exhibiting stable disease at three months. As the trial\nadvances into higher-dose cohorts, Anixa expects additional patient-level data\nover the next few months.\n\nThe webinar will also highlight Anixa's breast cancer vaccine, which\nsuccessfully completed its Phase 1 testing in 35 patients, meeting all primary\nendpoints, with no reported safety concerns and a 74% protocol-specified\nimmune-response rate. Developed with Cleveland Clinic and funded by the US\nDepartment of Defense, the vaccine targets α-lactalbumin, a protein\nassociated with breast cancer. Anixa is preparing a Phase 2 trial to evaluate\nthe vaccine in a neo-adjuvant setting alongside standard-of-care treatment,\nwith longer-term potential to prevent and treat breast cancer.\n\nManagement will also discuss Anixa's capital-efficient development strategy,\nupcoming clinical milestones, and potential strategic partnerships. As of July\n31, 2026, the Company held approximately $14 million in cash and short-term\ninvestments, with no debt, warrants, or preferred stock. Its\ncollaboration-based model enables Anixa to advance two clinical programs while\nmaintaining a lean operating structure.\n\nA live question and answer session will follow the presentation.\n\nTo register for the free webinar, please visit:\nhttps://www.redchip.com/webinar/ANIX/83349309450\n\nQuestions can be pre-submitted to ANIX@redchip.com or online during the live\nevent.\n\nAbout Anixa Biosciences, Inc.\n\nAnixa is a clinical-stage biotechnology company focused on the treatment and\nprevention of cancer. Anixa's therapeutic portfolio consists of liraltagene\nautoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in\ncollaboration with Moffitt Cancer Center, which uses a novel type of CAR-T,\nknown as chimeric endocrine receptor-T cell (CER-T) technology. This\ntechnology is differentiated from other cell therapies as the natural ligand\nof the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell\ninstead of an antibody fragment. Moffitt is a world leader in cancer\nimmunotherapy treatments, pioneering next-generation cell therapies such as\nCAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the\nimmune system. The Company's vaccine portfolio includes vaccines being\ndeveloped in collaboration with Cleveland Clinic to treat and prevent breast\ncancer and ovarian cancer, as well as additional cancer vaccines to address\nmany intractable cancers, including high incidence malignancies in lung,\ncolon, and prostate. These vaccine technologies focus on immunizing against\n\"retired\" proteins that have been found to be expressed in certain forms of\ncancer. The breast and ovarian cancer vaccines were developed at Cleveland\nClinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to\nroyalties and other commercialization revenues from the Company related to\nthese vaccine technologies. Anixa's unique business model of partnering with\nworld-renowned research institutions on all stages of development allows the\nCompany to continually examine emerging technologies in complementary fields\nfor further development and commercialization. To learn more, visit\nwww.anixa.com or follow Anixa on LinkedIn (https://pr.report/sbil), X\n(https://pr.report/sbim), Facebook (https://pr.report/sbin) and YouTube\n(https://pr.report/sbio).\n\nAbout Dr. Amit Kumar\n\nDr. Kumar has been an investor, founder, director and CEO of several\ntechnology enterprises, both public and private. As CEO, he took CombiMatrix\nCorporation public and ran it for a decade while listed on the NASDAQ Global\nMarket. He has worked in venture capital with OAK Investment Partners, and has\nbeen an advisor to investment funds, venture capital firms, and Fortune 500\ncompanies. He was on the Board of Directors of Acacia Research Corporation\nfrom 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences\nand he sits on the Board of other public and private companies. He has served\non the Board of the American Cancer Society since 2016. He received his AB in\nChemistry from Occidental College. After graduate studies at Stanford\nUniversity and Caltech, he received his Ph.D. from Caltech and followed that\nwith a post-doctoral fellowship at Harvard.\n\nAbout RedChip Companies\n\nRedChip Companies, an Inc. 5000 company, is an international investor\nrelations, media, and research firm focused on microcap and small-cap\ncompanies. Founded in 1992 as a small-cap research firm, RedChip gained early\nrecognition for initiating coverage on emerging blue chip companies such as\nApple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years,\nRedChip has evolved into a full-service investor relations and media firm,\ndelivering concrete, measurable results for its clients, which have included\nU.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among\nothers. Our newsletter, Small Stocks, Big Money™, is delivered online weekly\nto 60,000 investors. RedChip has developed the most comprehensive service\nplatform in the industry for microcap and small-cap companies. These services\ninclude the following: a worldwide distribution network for its stock\nresearch; retail and institutional roadshows in major U.S. cities; outbound\nmarketing to stock brokers, RIAs, institutions, and family offices; a digital\nmedia investor relations platform that has generated millions of unique\ninvestor views; investor webinars and group calls; a television show, Small\nStocks, Big Money™, which airs weekly on Bloomberg US and CNBC; TV\ncommercials in local and national markets; corporate and product videos;\nwebsite design; and traditional investor relation services, which include\npress release writing, development of investor presentations, quarterly\nconference call script writing, strategic consulting, capital raising, and\nmore.\n\nSign Up for RedChat\n\nRedChat™ is an AI-powered investment research assistant designed to give\ninvestors instant access to critical insights from SEC filings, press\nreleases, and corporate disclosures. Built to streamline small-cap and\nmicrocap stock research, RedChat analyzes thousands of public company\ndocuments and delivers clear, context-rich answers to investor questions in\nseconds. Instead of manually reviewing lengthy filings, investors can simply\nask RedChat about financial results, partnerships, business strategy, or\nrecent announcements and receive precise, source-based summaries. Investors\ncan experience RedChat and start exploring stocks today at\nwww.redchip.com/stocks or www.red.chat.\n\nTo learn more about RedChip's products and services, please visit:\nhttps://www.redchip.com/corporate/investor_relations\n\n\"Discovering Tomorrow's Blue Chips Today\"™\n\nFollow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/\n\nFollow RedChip on Facebook: https://www.facebook.com/RedChipCompanies\n\nFollow RedChip on Instagram: https://www.instagram.com/redchipcompanies/\n\nFollow RedChip on Twitter: https://twitter.com/RedChip\n\nFollow RedChip on YouTube: https://www.youtube.com/@redchip\n\nFollow RedChip on Rumble: https://rumble.com/c/c-3068340\n\nSubscribe to our Mailing List: https://www.redchip.com/newsletter/latest\n\nDisclaimer\n\nThis press release is for informational purposes only and does not constitute\nan offer to sell or a solicitation of an offer to buy any securities. Certain\nstatements regarding Anixa Biosciences, Inc. (\"Anixa\") and its business,\nclinical programs, therapeutic candidates, anticipated clinical milestones,\nfuture clinical trials, strategic collaborations, potential market\nopportunities, financial position, plans and prospects may constitute\nforward-looking statements and are subject to risks and uncertainties that\ncould cause actual results to differ materially from those expressed or\nimplied. Investors should review Anixa's filings with the Securities and\nExchange Commission for additional information regarding the Company and the\nrisks associated with an investment in its securities. RedChip Companies, Inc.\nprovides investor relations and media services to Anixa and receives\ncompensation for those services.\n\nVisit https://www.redchip.com/legal/disclosures for details. The information\nregarding Anixa contained in this release has been derived from information\nprovided by the Company or from publicly available sources. RedChip does not\nindependently verify all such information and makes no representation or\nwarranty as to its accuracy or completeness. Nothing contained herein should\nbe construed as investment advice or a recommendation to buy or sell any\nsecurity.\n\nContact:\n\nDave Gentry\nRedChip Companies Inc.\n1-407-644-4256 | 1-800-REDCHIP (733-2447)\nANIX@redchip.com\n\nSOURCE: RedChip Companies Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/join-anixa-biosciences-live-investor-webinar-advancing-innovativ-1236242)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSngdGWa-20261013","title":"Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine","author":"ACCESSWIRE","ticker":"ANIX","created":"2026-10-13T13:00:01.070Z","tickers":["ANIX"],"exchange":"NASDAQ","article_body":"ORLANDO, FL / ACCESS Newswire (https://www.accessnewswire.com/) / October 13,\n2026 / RedChip Companies will host an investor webinar on Tuesday, October 20,\n2026, at 4:15 p.m. ET with Anixa Biosciences, Inc. (Nasdaq:ANIX), a\nclinical-stage biotechnology company developing first-in-class therapies to\ntreat and potentially prevent cancer.\n\nThe exclusive event will feature Dr. Amit Kumar, Chairman and CEO, who will\ndiscuss Anixa's two clinical-stage oncology programs: lira-cel, a novel CAR-T\ntherapy for recurrent, treatment-resistant ovarian cancer, and a breast cancer\nvaccine with therapeutic and preventive potential. Both programs are being\nadvanced through collaborations with leading research institutions, Moffitt\nCancer Center and Cleveland Clinic.\n\nDr. Kumar will review progress in the Phase 1 trial of lira-cel, an\nFSHR-targeted CAR-T therapy designed to attack both ovarian cancer cells and\ntumor-associated blood vessels. Early clinical observations include\nencouraging survival in heavily pretreated patients, with one patient\nsurviving nearly 2.5 years following treatment, and the first patient at the\ncurrent dose level exhibiting stable disease at three months. As the trial\nadvances into higher-dose cohorts, Anixa expects additional patient-level data\nover the next few months.\n\nThe webinar will also highlight Anixa's breast cancer vaccine, which\nsuccessfully completed its Phase 1 testing in 35 patients, meeting all primary\nendpoints, with no reported safety concerns and a 74% protocol-specified\nimmune-response rate. Developed with Cleveland Clinic and funded by the US\nDepartment of Defense, the vaccine targets α-lactalbumin, a protein\nassociated with breast cancer. Anixa is preparing a Phase 2 trial to evaluate\nthe vaccine in a neo-adjuvant setting alongside standard-of-care treatment,\nwith longer-term potential to prevent and treat breast cancer.\n\nManagement will also discuss Anixa's capital-efficient development strategy,\nupcoming clinical milestones, and potential strategic partnerships. As of July\n31, 2026, the Company held approximately $14 million in cash and short-term\ninvestments, with no debt, warrants, or preferred stock. Its\ncollaboration-based model enables Anixa to advance two clinical programs while\nmaintaining a lean operating structure.\n\nA live question and answer session will follow the presentation.\n\nTo register for the free webinar, please visit:\nhttps://www.redchip.com/webinar/ANIX/83349309450\n\nQuestions can be pre-submitted to ANIX@redchip.com or online during the live\nevent.\n\nAbout Anixa Biosciences, Inc.\n\nAnixa is a clinical-stage biotechnology company focused on the treatment and\nprevention of cancer. Anixa's therapeutic portfolio consists of liraltagene\nautoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in\ncollaboration with Moffitt Cancer Center, which uses a novel type of CAR-T,\nknown as chimeric endocrine receptor-T cell (CER-T) technology. This\ntechnology is differentiated from other cell therapies as the natural ligand\nof the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell\ninstead of an antibody fragment. Moffitt is a world leader in cancer\nimmunotherapy treatments, pioneering next-generation cell therapies such as\nCAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the\nimmune system. The Company's vaccine portfolio includes vaccines being\ndeveloped in collaboration with Cleveland Clinic to treat and prevent breast\ncancer and ovarian cancer, as well as additional cancer vaccines to address\nmany intractable cancers, including high incidence malignancies in lung,\ncolon, and prostate. These vaccine technologies focus on immunizing against\n\"retired\" proteins that have been found to be expressed in certain forms of\ncancer. The breast and ovarian cancer vaccines were developed at Cleveland\nClinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to\nroyalties and other commercialization revenues from the Company related to\nthese vaccine technologies. Anixa's unique business model of partnering with\nworld-renowned research institutions on all stages of development allows the\nCompany to continually examine emerging technologies in complementary fields\nfor further development and commercialization. To learn more, visit\nwww.anixa.com or follow Anixa on LinkedIn (https://pr.report/sbil), X\n(https://pr.report/sbim), Facebook (https://pr.report/sbin) and YouTube\n(https://pr.report/sbio).\n\nAbout Dr. Amit Kumar\n\nDr. Kumar has been an investor, founder, director and CEO of several\ntechnology enterprises, both public and private. As CEO, he took CombiMatrix\nCorporation public and ran it for a decade while listed on the NASDAQ Global\nMarket. He has worked in venture capital with OAK Investment Partners, and has\nbeen an advisor to investment funds, venture capital firms, and Fortune 500\ncompanies. He was on the Board of Directors of Acacia Research Corporation\nfrom 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences\nand he sits on the Board of other public and private companies. He has served\non the Board of the American Cancer Society since 2016. He received his AB in\nChemistry from Occidental College. After graduate studies at Stanford\nUniversity and Caltech, he received his Ph.D. from Caltech and followed that\nwith a post-doctoral fellowship at Harvard.\n\nAbout RedChip Companies\n\nRedChip Companies, an Inc. 5000 company, is an international investor\nrelations, media, and research firm focused on microcap and small-cap\ncompanies. Founded in 1992 as a small-cap research firm, RedChip gained early\nrecognition for initiating coverage on emerging blue chip companies such as\nApple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years,\nRedChip has evolved into a full-service investor relations and media firm,\ndelivering concrete, measurable results for its clients, which have included\nU.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among\nothers. Our newsletter, Small Stocks, Big Money™, is delivered online weekly\nto 60,000 investors. RedChip has developed the most comprehensive service\nplatform in the industry for microcap and small-cap companies. These services\ninclude the following: a worldwide distribution network for its stock\nresearch; retail and institutional roadshows in major U.S. cities; outbound\nmarketing to stock brokers, RIAs, institutions, and family offices; a digital\nmedia investor relations platform that has generated millions of unique\ninvestor views; investor webinars and group calls; a television show, Small\nStocks, Big Money™, which airs weekly on Bloomberg US and CNBC; TV\ncommercials in local and national markets; corporate and product videos;\nwebsite design; and traditional investor relation services, which include\npress release writing, development of investor presentations, quarterly\nconference call script writing, strategic consulting, capital raising, and\nmore.\n\nSign Up for RedChat\n\nRedChat™ is an AI-powered investment research assistant designed to give\ninvestors instant access to critical insights from SEC filings, press\nreleases, and corporate disclosures. Built to streamline small-cap and\nmicrocap stock research, RedChat analyzes thousands of public company\ndocuments and delivers clear, context-rich answers to investor questions in\nseconds. Instead of manually reviewing lengthy filings, investors can simply\nask RedChat about financial results, partnerships, business strategy, or\nrecent announcements and receive precise, source-based summaries. Investors\ncan experience RedChat and start exploring stocks today at\nwww.redchip.com/stocks or www.red.chat.\n\nTo learn more about RedChip's products and services, please visit:\nhttps://www.redchip.com/corporate/investor_relations\n\n\"Discovering Tomorrow's Blue Chips Today\"™\n\nFollow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/\n\nFollow RedChip on Facebook: https://www.facebook.com/RedChipCompanies\n\nFollow RedChip on Instagram: https://www.instagram.com/redchipcompanies/\n\nFollow RedChip on Twitter: https://twitter.com/RedChip\n\nFollow RedChip on YouTube: https://www.youtube.com/@redchip\n\nFollow RedChip on Rumble: https://rumble.com/c/c-3068340\n\nSubscribe to our Mailing List: https://www.redchip.com/newsletter/latest\n\nDisclaimer\n\nThis press release is for informational purposes only and does not constitute\nan offer to sell or a solicitation of an offer to buy any securities. Certain\nstatements regarding Anixa Biosciences, Inc. (\"Anixa\") and its business,\nclinical programs, therapeutic candidates, anticipated clinical milestones,\nfuture clinical trials, strategic collaborations, potential market\nopportunities, financial position, plans and prospects may constitute\nforward-looking statements and are subject to risks and uncertainties that\ncould cause actual results to differ materially from those expressed or\nimplied. Investors should review Anixa's filings with the Securities and\nExchange Commission for additional information regarding the Company and the\nrisks associated with an investment in its securities. RedChip Companies, Inc.\nprovides investor relations and media services to Anixa and receives\ncompensation for those services.\n\nVisit https://www.redchip.com/legal/disclosures for details. The information\nregarding Anixa contained in this release has been derived from information\nprovided by the Company or from publicly available sources. RedChip does not\nindependently verify all such information and makes no representation or\nwarranty as to its accuracy or completeness. Nothing contained herein should\nbe construed as investment advice or a recommendation to buy or sell any\nsecurity.\n\nContact:\n\nDave Gentry\nRedChip Companies Inc.\n1-407-644-4256 | 1-800-REDCHIP (733-2447)\nANIX@redchip.com\n\nSOURCE: RedChip Companies Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/join-anixa-biosciences-live-investor-webinar-advancing-innovativ-1236242)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T13:00:01.1896944Z","server_sent_at_ms":1791896401189},"received_at":"2026-10-13T13:00:01.240Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/join-anixa-biosciences-live-investor-webinar-advancing-innovativ-1236242"},"analysis":{"id":"155938","press_release_id":"167649","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["IR-firm-distributed promotional content; RedChip receives compensation from Anixa","capital-efficient model with only ~$14M cash for two clinical programs may imply future financing needs"],"eventType":"other","narrative":"RedChip Companies will host an investor webinar with Anixa Biosciences on October 20, 2026 at 4:15 p.m. ET, featuring Chairman and CEO Dr. Amit Kumar.\n\nThe webinar recaps two clinical programs: the Phase 1 lira-cel CAR-T trial in ovarian cancer, where one heavily pretreated patient survived nearly 2.5 years, and a breast cancer vaccine that completed Phase 1 in 35 patients with a 74% immune-response rate.\n\nAnixa reported approximately $14 million in cash and short-term investments as of July 31, 2026, with no debt, warrants, or preferred stock.\n\nThe release is promotional IR content distributed via a compensated investor-relations firm and contains no new data or milestones.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor webinar promo with recycled clinical data -- suppress or low-priority."},"keyFigures":{"customDimensions":{"cash_as_of":"July 31, 2026","vaccine_phase1_patients":35,"lira_cel_longest_survival":"nearly 2.5 years","vaccine_immune_response_rate":"74%","cash_and_short_term_investments":"$14 million"}},"namedEntities":{"people":[{"name":"Dr. Amit Kumar","role":"Chairman and CEO of Anixa Biosciences"},{"name":"Dave Gentry","role":"RedChip Companies contact"}],"products":["lira-cel (liraltagene autoleucel)","breast cancer vaccine (α-lactalbumin-targeted)"],"companies":[{"name":"Anixa Biosciences, Inc.","ticker":"ANIX","relationship":"subject"},{"name":"RedChip Companies Inc.","relationship":"investor relations firm / webinar host"},{"name":"Moffitt Cancer Center","relationship":"research collaborator"},{"name":"Cleveland Clinic","relationship":"research collaborator"},{"name":"US Department of Defense","relationship":"vaccine program funder"}],"dollarAmounts":[{"amount":"$14 million","context":"cash and short-term investments as of July 31, 2026"}]},"materialImpact":{"score":1,"reasoning":"This is an investor-relations webinar announcement, not new clinical, financial, or corporate disclosure. Program details are recaps of prior data with no new results."},"tickerRelevance":{"others":[],"primary":"ANIX"},"globalImportance":12,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"ir-webinar-announcement","issuerAuthored":false,"promotionalContent":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"RedChip Companies will host an investor webinar with Anixa Biosciences on October 20, 2026 at 4:15 p.m. ET, featuring Chairman and CEO Dr. Amit Kumar.\n\nThe webinar recaps two clinical programs: the Phase 1 lira-cel CAR-T trial in ovarian cancer, where one heavily pretreated patient survived nearly 2.5 years, and a breast cancer vaccine that completed Phase 1 in 35 patients with a 74% immune-response rate.\n\nAnixa reported approximately $14 million in cash and short-term investments as of July 31, 2026, with no debt, warrants, or preferred stock.\n\nThe release is promotional IR content distributed via a compensated investor-relations firm and contains no new data or milestones.","key_figures":{"customDimensions":{"cash_as_of":"July 31, 2026","vaccine_phase1_patients":35,"lira_cel_longest_survival":"nearly 2.5 years","vaccine_immune_response_rate":"74%","cash_and_short_term_investments":"$14 million"}},"named_entities":{"people":[{"name":"Dr. Amit Kumar","role":"Chairman and CEO of Anixa Biosciences"},{"name":"Dave Gentry","role":"RedChip Companies contact"}],"products":["lira-cel (liraltagene autoleucel)","breast cancer vaccine (α-lactalbumin-targeted)"],"companies":[{"name":"Anixa Biosciences, Inc.","ticker":"ANIX","relationship":"subject"},{"name":"RedChip Companies Inc.","relationship":"investor relations firm / webinar host"},{"name":"Moffitt Cancer Center","relationship":"research collaborator"},{"name":"Cleveland Clinic","relationship":"research collaborator"},{"name":"US Department of Defense","relationship":"vaccine program funder"}],"dollarAmounts":[{"amount":"$14 million","context":"cash and short-term investments as of July 31, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T13:00:07.125Z","global_importance":12,"audience_relevance":18,"importance_components":{"tickerTier":"micro-cap","eventGravity":"ir-webinar-announcement","issuerAuthored":false,"promotionalContent":true}},"durationMs":5850,"modelName":"glm-5.3-flashx"}}